Shepherd G, Cam M C, Sambandam N, Abrahani M A, Rodrigues B
Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada.
Hypertension. 1998 Mar;31(3):878-84. doi: 10.1161/01.hyp.31.3.878.
Vascular endothelial-bound lipoprotein lipase (LPL), also known as heparin-releasable LPL, catalyzes the breakdown of the triglyceride component of lipoproteins and is rate-limiting for free fatty acid transport to tissues. We previously demonstrated that heparin-releasable LPL activity increases in diabetic Wistar rat hearts, whereas with the development of hypertension in spontaneously hypertensive rats (SHR), there is a concomitant and progressive reduction in LPL activity. The objective of the present study was to examine the regulation of cardiac LPL activity in SHR-diabetic rats. Heparin perfusion of the isolated Langendorff heart induced the release of LPL activity. SHR hearts demonstrated a reduction in peak heparin-releasable LPL activity, relative to Wistar controls. However, induction of streptozotocin-induced diabetes in SHR, as in Wistar rats, increased peak heparin-releasable LPL activity in perfused hearts. The elevated heparin-releasable LPL peak could not be accounted for by enhanced LPL synthesis in that both cellular and surface-bound LPL activities in myocytes from SHR-diabetic rats were low relative to control. Chronic (12-day) insulin treatment of SHR-diabetic rats reduced the augmented heparin-releasable LPL activity and increased cell-associated LPL activity. Moreover, acute (90-minute) treatment of SHR-diabetic rats with rapid-acting insulin also reduced the heparin-releasable LPL activity to normal, although it had no effect on the low cellular LPL activity. These results demonstrate that the diabetes-induced augmentation of cardiac LPL counteracts the reduction in enzyme activity associated with hypertension. This may serve to increase the delivery of free fatty acid to the heart, and the resultant metabolic changes may lead to the severe cardiomyopathy observed in the hypertensive-diabetic rat heart.
血管内皮结合脂蛋白脂肪酶(LPL),也称为肝素可释放LPL,催化脂蛋白中甘油三酯成分的分解,是游离脂肪酸转运至组织的限速酶。我们之前证明,糖尿病Wistar大鼠心脏中肝素可释放LPL活性增加,而在自发性高血压大鼠(SHR)中随着高血压的发展,LPL活性会随之逐渐降低。本研究的目的是检测SHR-糖尿病大鼠心脏LPL活性的调节情况。对离体Langendorff心脏进行肝素灌注可诱导LPL活性释放。相对于Wistar对照,SHR心脏的肝素可释放LPL活性峰值降低。然而,与Wistar大鼠一样,在SHR中诱导链脲佐菌素糖尿病会增加灌注心脏中肝素可释放LPL活性峰值。肝素可释放LPL峰值升高不能用LPL合成增强来解释,因为相对于对照,SHR-糖尿病大鼠心肌细胞中的细胞内和表面结合LPL活性均较低。对SHR-糖尿病大鼠进行慢性(12天)胰岛素治疗可降低增强的肝素可释放LPL活性,并增加细胞相关LPL活性。此外,用速效胰岛素对SHR-糖尿病大鼠进行急性(90分钟)治疗也可将肝素可释放LPL活性降低至正常水平,尽管它对低细胞LPL活性没有影响。这些结果表明,糖尿病诱导的心脏LPL增加可抵消与高血压相关的酶活性降低。这可能有助于增加游离脂肪酸向心脏的输送,而由此产生的代谢变化可能导致高血压-糖尿病大鼠心脏中观察到的严重心肌病。